Clinical Trials
32 trialsIMFINZI-subQ
AstraZeneca
Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer
National Cancer Institute (NCI)
Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma
Mayo Clinic
Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab
University of California, San Diego
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer
City of Hope Medical Center
Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer
Washington University School of Medicine
Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)
University of California, Irvine
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
I-Mab Biopharma US Limited
A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma
Zhejiang University
A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1)
National Cancer Institute, Naples
Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer
University of Maryland, Baltimore
Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer
University of Southern California
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.
NeoTX Therapeutics Ltd.
Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers
Abramson Cancer Center at Penn Medicine
SIRT With Tremelimumab and Durvalumab for Resectable HCC
Dana-Farber Cancer Institute
iRE-C
University of Iowa
Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases
University of Colorado, Denver
Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery
M.D. Anderson Cancer Center
PREDICT
University Medical Center Groningen
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies
AstraZeneca
A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab
Ludwig Institute for Cancer Research
MEDIPLEX
Centre Leon Berard
A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours
AstraZeneca
A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies
Eli Lilly and Company
Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors
AstraZeneca
Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver
City of Hope Medical Center
A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours
AstraZeneca
A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer
Eli Lilly and Company
Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer
NYU Langone Health